| ACC | American College Of Cardiology |
| ACEi | Angiotensin-converting enzyme inhibitor |
| AHA | American Heart Association |
| ALT | Alanine aminotransferase |
| ARNI | Angiotensin receptor–neprilysin inhibitor |
| ARR | Absolute risk reduction |
| AST | Aspartate aminotransferase |
| BB | Beta-blocker |
| BMI | Body mass index |
| CHF | Congestive heart failure |
| CI | Confidence interval |
| CKD | Chronic kidney disease |
| COPD | Chronic obstructive pulmonary disease |
| CT | Computed tomography |
| CV | Cardiovascular |
| CXR | Chest x-rays |
| eGFR | Estimated glomerular filtration rate |
| ESC | European Society of Cardiology |
| HF | Heart failure |
| HFH | Heart failure hospitalization |
| HFrEF | Heart failure with reduced ejection fraction |
| HR | Hazard ratio |
| IVS | Interventricular septum |
| K | Potassium |
| LV | Left ventricle |
| LVEDD | Left ventricular end diastolic diameter |
| LVEF | Left ventricular ejection fraction |
| MRI | Magnetic resonance imaging |
| MRA | Mineralocorticoid receptor antagonists |
| Na | Sodium |
| NNT | Number needed to treat |
| NYHA | New York Heart Association |
| PW | Posterior wall |
| SD | Standard deviation |
| SE | Standard error |
| SGLT2i | Sodium–glucose cotransporter 2 inhibitor |
| sPAP | Systolic pulmonary arterial pressure |
| T2DM | Diabetes mellitus type II |
| TAPSE | Tricuspid annular plane systolic excursion |
| TTE | Transthoracic echocardiography |